Samsung Biologics Surpasses 3 Trillion Won in Annual Cumulative Orders in Just 5 Months

Secures Four New Contracts
Reaches 60 Percent of Previous Year's Order Volume

Samsung Biologics has signed a series of large-scale contracts with global pharmaceutical companies, surpassing a cumulative annual order amount of 3 trillion won in just five months.

Samsung Biologics Plant 4. Samsung Biologics

On May 26, Samsung Biologics announced through a public filing that it had signed two contract manufacturing (CMO) agreements worth a total of 440.5 billion won (319.57 million USD) with pharmaceutical companies based in Europe and Asia. The contracts are valued at 242 billion won (175.55 million USD) with the European company and 198.5 billion won (144.03 million USD) with the Asian company, respectively. The contract periods run until December 31, 2030, and December 31, 2033, respectively. The names of the clients and products have not been disclosed due to confidentiality agreements.

Samsung Biologics has signed a total of four new contracts this year, based on public disclosures. Beginning with the first contract in January, the company has continued to secure new orders from the United States, Asia, and Europe. In five months, Samsung Biologics has achieved an order volume of 3.2525 trillion won, exceeding 60% of the previous year's total annual order amount of 5.4035 trillion won.

Currently, Samsung Biologics counts 17 of the world's top 20 pharmaceutical companies as its clients. Leveraging its production capacity, quality, and extensive track record as core competitive advantages, the company has accumulated a total order value of approximately 18.2 billion USD since its founding.

Samsung Biologics is also accelerating the expansion of its production capacity to proactively respond to increasing demand for biopharmaceuticals. Plant 5, which began full-scale operation in April, is a 180,000-liter facility that incorporates the best practices of Plants 1 through 4. With this addition, Samsung Biologics now boasts the world's largest total production capacity at 784,000 liters.

The company continues to achieve outstanding results in terms of quality competitiveness as well. In 2024, Samsung Biologics recorded a 99% batch success rate. As of April 2025, it has obtained a total of 356 manufacturing approvals from major global regulatory agencies, including those in the United States, Europe, and Japan. The number of approvals continues to rise in line with expanded production capacity, and the company maintains an industry-leading regulatory inspection pass rate.

Meanwhile, Samsung Biologics is actively participating in various conferences to strengthen its connections with global clients. Starting with the JP Morgan Healthcare Conference in January, the company held meetings with key and potential clients at DCAT Week in March and PEGS Boston in May. In June, Samsung Biologics plans to participate in the 2025 BIO International Convention (BIO USA), the world's largest pharmaceutical and biotechnology exhibition, to be held in Boston, USA.

This content was produced with the assistance of AI translation services.